Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is an increase in the shareholding of Mr. S M Bicknell. This change resulted from the purchase of 842 Ordinary shares on March 14, 2011, following the reinvestment of dividends within an Individual Savings Account (ISA). The transaction occurred at a price of £11.96 per Ordinary share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: March 14, 2011
- Individual Involved: Mr. S M Bicknell
- Shares Acquired: 842 Ordinary shares
- Transaction Price: £11.96 per share
- Transaction Type: Dividend reinvestment within an ISA
- Reporting Authority: Victoria Whyte, Company Secretary